Neumora Therapeutics is trading at $0.69, down 5.07%, amid biotech weakness and broad risk-off pressure. - No company-specific announcement, earnings release, clinical update, or analyst action was identified for September 24, 2026. - Available coverage points to earlier August updates, not a fresh catalyst. - Treasury yields reached multiyear highs amid renewed inflation concerns.